Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
NCT01753310 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the protocol is to evaluate the efficacy and safety of Dysport® using 2 mL dilution compared with placebo for the treatment of Cervical Dystonia.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Botulinum toxin type A
Study Locations (20)
Florida
- Parkinson's & Movement Disorders Center of Boca Raton — Boca Raton
- University of Florida Center for Movement Disorders and Neurorestoration — Gainesville
- Emerald Coast Center for Neurological Disorders — Pensacola
- PD Treatment Center of SW FL — Port Charlotte
- University of South Florida — Tampa
- Guilford Neurologic Associates — West Palm Beach
- Premiere Research Institute at Palm Beach Neurology — West Palm Beach
California
- East Bay Physician's Group — Berkeley
- Parkinson's and Movement Disorder Institute — Fountain Valley
- Loma Linda University Healthcare, Department of Neurology — Loma Linda
- USC Keck School of Medicine — Los Angeles
- UC Davis Medical Center — Sacramento
Arizona
- Movement Disorders Center of Arizona, LLC — Scottsdale
- University of Arizona — Tucson
Colorado
- University of Colorado at Denver Health Sciences — Aurora
- Advanced Neurosciences Research — Fort Collins
Alabama
- University of Alabama at Birmingham — Birmingham
Connecticut
- Associated Neurologists of Southern Connecticut — Fairfield
District of Columbia
- Georgetown University Hospital — Washington D.C.
Georgia
- Emory University — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753310
The ClinicalTrials.gov registry entry for NCT01753310 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 205 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cervical Dystonia appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01753310 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01753310 about?
NCT01753310 is a clinical study titled "Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.". The purpose of the protocol is to evaluate the efficacy and safety of Dysport® using 2 mL dilution compared with placebo for the treatment of Cervical Dystonia.
What is the current status of trial NCT01753310?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 134 participants. The study started on 2013-01. Estimated completion is 2015-01.
What conditions does trial NCT01753310 study?
This clinical trial studies the following conditions: Cervical Dystonia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01753310?
The interventions under investigation include: Placebo (DRUG), Botulinum toxin type A (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01753310?
This trial is sponsored by Ipsen, which has 205 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01753310 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.